Achieve Life Sciences Inc. - Common ...





Please Login or Register

Login|Register FREE

Stock Price
Open: 1.15
Prev. Close: 1.15
Low/Hi: 1.14 - 1.18
52-Week: 1.01 - 6.27
Equity: 17,515
90-Day Avg: 294,153
Todays Stock Vol: 40.9
20-Day (HV): 85.3
52-Week (HV): 122.2
Div. Yield:
Earnings: 21-Sep (Est.)
P/E Ratio:
Market Cap: 15.2 M
Short Int Pct: 0.0%
Pct Held By Inst.: 3.8%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

About ACHV

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Primary Exchange: NASDAQ
SIC In Vitro & In Vivo Diagnostic Substances
NAICS In-Vitro Diagnostic Substance Manufacturing

ACHV is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
ITOT iShares Core S&P Total U.S. Stock Market ETF 13.9 B 1.39164E+10 3,460 3460 0.0% 0 22 K 21752
VTI Vanguard Total Stock Market ETF 93.3 B 9.33E+10 3,629 3629 0.0% 0 20 K 19759
VXF Vanguard Extended Market ETF 5.9 B 5.9E+09 3,259 3259 0.0% 0 2 K 2150

Wait, Before You Leave...

Want to Know More About ACHV Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon